between 1960 and 2015 in English language. Phase II, III or IV clinical trials with atleast one study arm assessing a treatment of interest were included. PRO studies (not limited to RCTs) reporting quality-of-life (QoL) data for these compounds were included. Additionally, information was extracted from product package inserts of molecules within FDA indication. Archives of 27 HTA bodies were searched for qualifying HTAs of these compounds as well. Patient characteristics, primary and secondary endpoints, safety, QoL and reimbursement decisions were extracted exhaustively from qualifying studies and HTAs. Results: So far, data are available for 15 cancers, including 90 agents in 487 studies. The interactive, user-friendly MS-Excel® based tool can be used to study any selected cancer, including conduct meta-analyses, generate summaries and reports of clinical, PRO and HTA data. The registry provides functionality for a user to make desired assessments via multiple variables such as line of treatment, tumor-stage, molecule, grade of adverse events and so on. ConClusions: OncoLitBank provides up-to-date data and a robust platform that can be easily used for systematic reviews, to conduct direct and indirect comparisons through meta-analyses, to inform economic models, perform landscape analyses, produce value dossiers,and to create target product profiles and value development plans. Expansion of searches to other literature databases and trial registries and inclusion of economic and epidemiology studies are underway.